Australia - English - Department of Health (Therapeutic Goods Administration)

scentia pharmaceuticals pty ltd - calcitriol -

Canada - English - Health Canada

odan laboratories ltd - calcitriol - capsule - 0.25mcg - calcitriol 0.25mcg - vitamin d

Canada - English - Health Canada

odan laboratories ltd - calcitriol - capsule - 0.5mcg - calcitriol 0.5mcg - vitamin d

Canada - English - Health Canada

fresenius kabi canada ltd - calcitriol - solution - 1mcg - calcitriol 1mcg - vitamin d

United States - English - NLM (National Library of Medicine)

patrin pharma, inc - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. calcitriol should not be given to patients with hypercalcemia or evidence of vitamin d toxicity. use of calcitriol in patients with known hypersensitivity to calcitriol (or drugs of the same class) or any of the inactive ingredients is contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: butylated hydroxyanisole; iron oxide red; purified water; gelatin; iron oxide yellow; fractionated coconut oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxytoluene - calciprox is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. calciprox is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. calciprox is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - calcitriol -

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - calcitriol 0.25ug;   - soft gelatin capsule - 0.25 mcg - active: calcitriol 0.25ug   excipient: butylated hydroxyanisole butylated hydroxytoluene coconut oil gelatin glycerol iron oxide black purified water quinoline yellow shellac sorbitol titanium dioxide - · established postmenopausal osteoporosis

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - calcitriol 0.5ug;   - soft gelatin capsule - 0.5 mcg - active: calcitriol 0.5ug   excipient: butylated hydroxyanisole butylated hydroxytoluene coconut oil gelatin glycerol iron oxide black patent blue v purified water quinoline yellow shellac sorbitol titanium dioxide - · established postmenopausal osteoporosis